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Both aflatoxin and the human immunodeficiency virus (HIV) cause immune suppression and millions of HIV-infected people
in developing countries are chronically exposed to aflatoxin in their diets. We investigated the possible interaction of aflatoxin
and HIV on immune suppression by comparing immune parameters in 116 HIV positive and 80 aged-matched HIV negative
Ghanaians with high (≥0.91 pmol/mg albumin) and low (<0.91 pmol/mg albumin) aflatoxin B1 albumin adduct (AF-ALB)
levels. AF-ALB levels and HIV viral load were measured in plasma and the percentages of leukocyte immunophenotypes and
cytokine expression were determined using flow cytometry. The cross-sectional comparisons found that (1) among both HIV
positive and negative participants, high AF-ALB was associated with lower perforin expression on CD8+ T-cells (P = .012);
(2) HIV positive participants with high AF-ALB had significantly lower percentages of CD4+ T regulatory cells (Tregs; P =
.009) and naive CD4+ T cells (P = .029) compared to HIV positive participants with low AF-ALB; and (3) HIV positive
participants with high AF-ALB had a significantly reduced percentage of B-cells (P = .03) compared to those with low AF-
ALB. High AF-ALB appeared to accentuate some HIV associated changes in T-cell phenotypes and in B-cells in HIV positive
participants.
Copyright © 2008 Yi Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Numerous studies conducted in animals and in animal and
human cell cultures have shown that aflatoxin exposure
can suppress immune function especially cell-mediated
immune responses [1, 2]. More specifically, these studies
on the immunotoxic eﬀect of aflatoxin have shown that
exposure to aflatoxin decreased T or B lymphocyte activity
[3, 4], impaired macrophage/neutrophil eﬀector functions
[5–8], modified synthesis of inflammatory cytokines [8,
9], suppressed NK cell-mediated cytolysis [10], decreased
resistance to infectious diseases [2, 11–15], induced reac-
tivation of chronic infection [16, 17], decreased immunity
to vaccination [18, 19], and impaired immune function in
developing animals [7, 20].
However, only two studies have been conducted on
the immune eﬀects of aflatoxin in humans exposed to
low levels of aflatoxin in contaminated foods. One study
conducted in Gambian children reported that secretory
immunoglobulin A in saliva may be reduced by dietary
levels of aflatoxin [21]. We previously reported that the
percentages of CD8+ T-cells that expressed perforin, or
both perforin and granzyme A were significantly lower
in participants with high AFB1-albumin adduct (AF-ALB)
levels in plasma compared to those with low AF-ALB
[22]. We also found that low levels of CD3+CD69+
and CD19+CD69+ cells were significantly associated with
high AF-ALB levels. These alterations in immunologi-
cal parameters in participants with high AF-ALB levels
could result in impairments in cellular immunity in these
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individuals that could decrease their resistance to infec-
tions.
Hendrickse et al. [23] investigated the reasons for
the rapid progression of human immunodeficiency virus
(HIV) and acquired immune deficiency syndrome (AIDS) in
heroin addicts in the Netherlands and Scotland. They found
that street heroin was often contaminated with aflatoxin,
and that aflatoxin derivatives were commonly found in
the body fluids of the addicts. They speculated that the
accelerated rate of HIV progression was due to aflatoxin-
related immune suppression, but did not undertake stud-
ies to examine this. This suggestion of synergy between
aflatoxin and HIV progression is also supported by the
broad correlation between estimated aflatoxin exposure and
the commonly perceived faster rate of HIV progression in
Africa than in developed countries in Europe or the United
States of America [24, 25]. The HIV pandemic is critical
enough for this possibility to be investigated as a matter of
urgency.
HIV infection results in impaired immune function
that can be measured by changes in immunphenotypically
defined lymphocyte subsets and other in vitro functional
assays. The altered expression of lymphocyte surface anti-
gens reflects the dynamic interaction between the immune
system and HIV. Investigation of the eﬀect of aflatoxin
on the immune system in HIV positive individuals is
urgently needed since both aflatoxin and HIV are immune
suppressive and millions of people who are chronically
exposed to aflatoxin in their diet in developing countries
are also HIV positive. In this study, we examined the
potential immune suppressive interaction of aflatoxin and
HIV by measuring a broad array of immune indices in
HIV-infected individuals with high and low AF-ALB lev-
els. HIV negative participants were included as a control
group.
2. MATERIALS AND METHODS
2.1. Study design and study participants
This was a cross-sectional analysis of 116 HIV positive
individuals and 80 HIV negative control participants. The
HIV positive patients and HIV negative controls of compa-
rable age were recruited from the St. Markus Hospital and
surrounding communities in Kumasi, Ghana. The protocol
for the study was approved by the Institutional Review
Board of the University of Alabama at Birmingham (UAB)
and the Medical School Ethics Committee of the Kwame
Nkrumah University of Science and Technology (KNUST)
and participants gave informed consent. The participants
were asked to complete a survey on socio-demographic
characteristics, and a 20 mL blood sample was collected from
each in EDTA vacutainer tubes. Plasma was separated and
peripheral blood mononuclear cells (PBMCs) were prepared
using ficoll-hypaque density gradients as previously done
[26]. PBMCs were stored frozen in liquid nitrogen and
shipped to UAB for analysis.
2.2. Determination of AF-ALB levels in plasma
by radioimmunoassay
AF-ALB levels in plasma of study participants were deter-
mined by radioimmunoassay (RIA) as published previously
[27]. Briefly, human plasma samples were concentrated by
high-speed centrifugal filtration using Microcon-50 micro-
concentrator with a 50 000 mol. wt. filter cutoﬀ. The con-
centrated protein was resuspended in 100–150 µL PBS and
the amount of human plasma albumin determined in each
sample using a bromocresol purple dye binding method. In
addition, the amount of total protein was determined by the
procedure of Bradford (Pierce Biotechnology Inc., Rockford,
IL). Total protein was then digested with Pronase (Cal-
biochem, La Jolla, Calif, USA; 70 000 proteolytic units/g dry
weight was dissolved in PBS at 10 mg/mL) at a ratio of 4 : 1
(Protein : pronase) in a shaking water bath (50 strokes/min)
at 37◦C for 16–18 hours. Digestion was stopped by cooling
on ice. Two volumes ice-cold acetone were added and the
sample mixed and allowed to remain at 4◦C for 1 hour.
The suspension was then centrifuged at 11 000 rpm (9800 g)
for 15 minutes. The resulting supernatant containing the
bound aflatoxin was decanted and dried in vacuo using
a savant speed-vac concentrator. The RIA procedure was
used to quantify aflatoxin B1-albumin adducts in duplicate
human plasma protein digests each containing 2 mg protein.
Nonspecific inhibition in the assay was determined by
processing pooled normal human plasma standards obtained
from Sigma Aldrich (St. Louis, MO, USA) and the average
value of the background was subtracted from the values of
test samples in calculating AFB1-albumin adduct levels. The
standard curve for the RIA was determined using a nonlinear
regression method [28] and values were expressed as the
amount of AFB1 per mg albumin [27]. The detection limit
of the assay was 0.01 pmol/mg albumin.
2.3. Determination of percentages of leukocyte
immunophenotypes using flow cytometry
We determined the percentages of leukocyte immunophe-
notypes in PBMCs from the study participants. The
percentages of T-cells (CD3+), subsets of T-cells (CD4+
and CD8+), B-cells (CD19+), and NK-cells (CD3-
CD56+) were measured by flow cytometry. Naive CD4
cells were defined as CD45RA+CD62L+ and memory
cells as CD45RO+CD45RA-. The expression of the
costimulatory molecule CD28, activation marker HLA-
DR, and CD38 on CD4 and CD8 T-cells were also
measured. CD8+ T-cell subset classification has been
proven useful in monitoring the immune system in
several clinical situations [29]. Therefore, we classified
CD8+ T-cell subsets into naive (CD8+CD27+CD45RA+),
memory (CD8+CD27+CD45RA-), and eﬀector (CD8+
CD27-CD45RA+) CD8+ T-cells by flow cytometry. Subtypes
of NK-cells, CD3-CD56+CD16-, and CD3-CD56+CD16+
were determined. The percentages of activated (marker
CD69) CD3+ T-cells and CD19+ B-cells (CD3+CD69+
and CD19+CD69+), and CD4+CD25+, CD4+CD25+
CD45RO+ T regulatory cell were also measured.
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PBMCs were incubated with combinations of fluorescein
FITC-, PE-, PerCP-labeled monoclonal antibodies (MAbs)
against CD3, CD4, CD8, CD16, CD19, CD25, CD27, CD38,
CD45RA, CD45RO, CD56, CD62, CD69, and HLA-DR
(BD PharMingen, San Diego, Calif) for 30 minutes at 4◦C.
Isotype-matched irrelevant FITC-, PE-, and PerCP-labeld
MAbs (BD PharMingen, San Diego, Calif) were used as
controls in the experiments. After washing the cells three
times in PBS, cell fluorescence for each phenotype was
analyzed using Becton Dickinson (San Diego, Calif, USA),
FACS, and CELLQuest software.
2.4. Determination of cytokine expressing
CD8+ and CD3-CD56+ cells
CD8+ T-cell cytokine expression (perforin and granzyme A)
was measured by intracellular cytokine staining and multi-
parameter flow cytometry. Also, the cytotoxicity potential of
NK-cells was examined by detecting perforin expression in
phenotypically defined NK-cells (CD3-CD56+).
For intracellular cytokine staining, PBMCs (1 × 106)
were collected in dPBS and washed once with cold dPBS
containing 1% BSA. Cells were then resuspended in 100 µL
of staining buﬀer (PBS supplemented with 0.1% sodium
azide and 1% FBS pH 7.4) and the phenotypic MAb (CD3,
CD8, and CD56) and incubated at 4◦C for 30 minutes. After
staining, the cells were washed with PBS and resuspended in
1 mL of fix/perm buﬀer (BD PharMingen, San Diego, Calif).
The cells were then fixed for 30 minutes at 4◦C, washed,
resuspended in 3 mL perm staining buﬀer and incubated
with cytokine antibodies (antiperforin, antigranzyme A)
(BD PharMingen, San Diego, Calif) in the presence of
50 uL of permeabilization buﬀer for 30 minutes at 4◦C. The
cells were then washed with perm buﬀer and resuspended
in 300 µL of fixative buﬀer (BD PharMingen) for flow
cytometric analysis on a Becton Dicknson FACS using
CELLQuest software.
2.5. Quantitative viral load assay
HIV RNA was measured using a quantitative reverse
transcriptase polymerase chain reaction assay (Amplicor
Monitor, Roche Diagnostic System, Brandersburg, NJ, USA).
Virus from 0.2 mL of plasma was lysed using the kit lysis
buﬀer and the HIV RNA was precipitated using isopropanol
and pelleted by centrifugation. After washing with ethanol,
the RNA was resuspended using the kit dilution buﬀer.
Extracted RNA was amplified and detected according to the
manufacturer’s instructions, and results were reported as
HIV RNA copies/mL. All undetectable values (below 400
copies) were assigned a value of 399.
2.6. Statistical analysis
Data were entered and analyzed using Windows SPSS version
11.5 (SPSS Inc., Clay, NC, USA). Data are expressed as the
means ± SD and the median. For analysis, HIV negative
and HIV positive participants were divided into high and
low AF-ALB subgroups based on the median AF-ALB
level for the group. Groups were compared by intragroup
comparisons (high versus low, among either HIV positive or
HIV negative participants) and by intergroup comparisons
(HIV positive versus HIV negative participants, among
either high or low AF-ALB), using Mann-Whitney U-tests.
Possible correlates of AF-ALB-associated accelerated HIV
disease progression included those indices that were similarly
and significantly associated with AF-ALB, as determined by
intragroup comparisons among both HIV positive and HIV
negative participants, and with HIV infection, as determined
by at least 1 intergroup comparison among high and low
AF-ALB participants. A probability value of P < .05
was considered statistically significant. Correlations using
nonparametric methods were also conducted to examine the
association between AF-ALB and the immune parameters
for the entire group and for HIV positive and HIV negative
groups separately.
3. RESULTS
3.1. Demographic and selected clinical
characteristics of participants
Demographic and clinical characteristics for the 116 HIV
positive study participants and 80 HIV negative controls
are summarized in Table 1. The mean age for the HIV
positive group was 38.25 ± 9.44 years and for the HIV
negative group was 40.77 ± 17.52 years. Approximately 65%
of HIV positive participants were females compared to 44%
females in the HIV negative group. AF-ALB levels for the 196
study participants ranged from 0–3.48 pmoL/mg albumin
with a mean of 1.01 ± 0.53 and median of 0.91 pmoL/mg
albumin. The mean AF-ALB was 1.01 ± 0.61 with median
of 0.91 pmoL/mg albumin for the HIV positive group and
1.01 ± 0.41 with median of 0.91 pmoL/mg albumin for the
HIV negative control group. Both groups of participants
were divided into high AF-ALB (≥0.91)and low AF-ALB
(<0.91) subgroups based on the median AF-ALB levels. For
HIV positive participants, the mean virus load was higher
among the high AF-ALB group compared to the low AF-ALB
group (85, 049 versus 70, 260 copies/mL), but this diﬀerence
was not statistically significant (P = .709). The mean CD4+
T-cell count in the HIV positive participants was 307.46 ±
248.37 cells/µL with a range of 37–1505 cells/µL. The mean
CD4+ T-cell count in the HIV negative participants was
1099.04 ± 454.91 cells/µL (range 472–2099 cells/µL). Based
on the CDC classification system [30], 17 HIV positive
patients were placed in category A, 52 in category B, and 47
in category C.
3.2. T, B, and NK cell phenotypes of
intergroup and intragroup comparisons
Nominally, significant inter- and intragroup diﬀerences are
summarized in Figure 1 and Table 2. When intergroup
comparisons were made, HIV associated diﬀerences were
mostly similar among both high AF-ALB and low AF-ALB
groups. Relative and absolute CD4+ T-cells were significantly
decreased in HIV positive participants compared to HIV
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Table 1: Demographic and clinical characteristics of HIV positive and HIV negative study participants.
Characteristic
HIV positive HIV negative
High AF-ALB Low AF-ALB High AF-ALB Low AF-ALB
Total number of participants 58 58 40 40
Age (mean ± SD years) 38.28±9.65 38.22±9.30 39.50±18.25 42.08±16.86
Gender number (%)
Male 24 (41.4) 17 (29.3) 23 (57.5) 22 (55)
Female 34 (58.6) 41 (70.7) 17 (42.5) 18 (45)
Viral load (mean ± SD copies/ml) 85049±230696 70260±193163 0 0
CD4 count (mean ± SD cells/µL) 316±266 298±230 1001±209 1197±614
CDC classification number (%)
A 10 (17.3) 7 (12.1)
B 25 (43.1) 27 (46.5)
C 23 (39.7) 24 (41.4)
AF-ALB (mean ± SD pmol/mg albumin) 1.44±0.56 0.59±0.24 1.31±0.36 0.70±0.14
Aflatoxin B1 albumin adducts (AF-ALB)—Mean± SD = 1.01±0.53 pmoL/mg albumin; median = 0.91 pmoL/mg albumin; range = 0–3.48 pmoL/mg albumin.
“High AF-ALB” participants were ≥0.91 pmoL/mg albumin; “low AF-ALB” participants were <0.91 pmoL/mg albumin.
SD = standard deviation.
negative controls (Figure 1(a)) and the proportions of CD8+
T-cells were higher in HIV positive participants than in
the negative controls (P = .000, Figure 1(b)). Diﬀerences
in lymphocyte antigen expression that were evident in the
HIV positive group were the CD28+ and HLA-DR+CD38+
percentages within both the CD4+ and CD8+ lympho-
cyte populations (all P ≤ .001, Table 2, Figures 1(c),
1(d), 1(i), and 1(j)). There were fewer CD4+CD25+ and
CD4+CD25+CD45RO+ regulatory T-cells in HIV positive
participants than HIV negative controls among both high
and low AF-ALB groups (Table 2, Figure 1(k). The diﬀerence
was statistically significant among the high AF-ALB group
(P = .000) and was not statistically significant among the
low AF-ALB group (P = .061).
HIV infection was associated with less naive CD8+
(CD45RA+CD62L+CD8+) T-cells (Table 2, Figure 1(f)),
and more memory CD8+ (CD45RO+CD45RA-CD8+) T-
cells (Table 2, Figure 1(h)) among both high AF-ALB (P =
.017, P = .006) and low AF-ALB groups (P = .003, P =
.002). There were more CD8+CD27-CD45RA+ cells in HIV
positive participants than HIV negative controls (Table 2,
Figure 1(l)) among the low AF-ALB group (P = .038) and
less CD8+CD27+CD45RA+ cells among the high AF-ALB
group (P = .03, Table 2). When CD8+ cells were analyzed
for the presence of intracellular perforin and granzyme
A without stimulation, we found that the percentages of
CD8+ T-cells containing both perforin and granzyme A were
statistically significantly higher in HIV positive participants
with high AF-ALB (P = .000) and low AF-ALB (P ≤ .003)
compared with HIV negative controls (Table 2, Figures 1(m)
and 1(n)).
There was lower CD69 expression on CD19+ B-cells in
HIV positive participants among both high and low AF-ALB
group (Table 2, Figure 1(p)), but this diﬀerence was only
statistically significant in the low AF-ALB group (P = .000).
No significant HIV associated diﬀerence in CD3-CD56+ and
perforin expressing NK-cells were apparent by intergroup
comparison among either the high AF-ALB or low AB-ALB
groups. With the exception of CD19+CD69+, CD8+CD27-
CD45RA+, and CD8+CD27+CD45RA+ cells, many of the
significant T-cell perturbations that were associated with
HIV infection in high AF-ALB HIV positive participants
were present in their low AF-ALB counterparts.
When intragroup comparisons were made, aflatoxin
associated diﬀerences depended in part on the HIV serosta-
tus of the participants. Among both the HIV positive and
HIV negative participants, higher AF-ALB was associated
with lower expression of perforin on CD8+ T-cells (Table 2,
Figure 1(m)). Lower perforin and granzyme A expressing
CD8+ T-cells also were seen in both groups (Table 2,
Figure 1(n)), but the diﬀerence was only statistically signif-
icant for the HIV negative groups (P = .01). Additional
aflatoxin associated diﬀerences among HIV positive partic-
ipants included lower percentage of CD4+CD25+CD45RO+
regulatory T-cells (P = .009), which was associated with
HIV infection in both high and low AF-ALB HIV positive
participants (Table 2, Figure 1(k)), and lower percentage
of naive CD4+ (CD4+CD45RA+CD62L+) T-cells (Table 2,
Figure 1(e)) in the high AF-ALB group.
AF-ALB associated reduction in the B-cells was apparent
in HIV positive participants (P = .03) but not in HIV
negative participants (Table 2, Figure 1(o)). High AF-ALB
associated diﬀerences among HIV negative controls included
less CD69 expression on both CD3+ T-cells (P = .024) and
CD19+ B-cells (P = .027) (Table 2, Figure 1(p)).
No significant aflatoxin-related diﬀerences in NK (CD3-
CD56+ or CD3-CD56+CD16+) cells and perforin express-
ing NK (CD3-CD56+Perforin) cells were apparent by intra-
group comparisons among either the HIV positive or the
HIV negative participants (Table 2, Figures 1(q) and 1(r)).
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Figure 1: Percentages of T-, B-, and NK-cells in PBMCs in relation to aflatoxin B1 albumin adduct (AF-ALB) levels and HIV infection. The
percentages are shown for HIV positive high AF-ALB (n = 58) and low AF-ALB (n = 58) groups, and HIV negative high AF-ALB (n = 40)
and low AF-ALB (n = 40) groups.
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When we conducted correlation analyses between AF-
ALB and the immune parameters among HIV positive par-
ticipants, we found significant correlations between AF-ALB
and perforin-expressing CD8+ T-cells (r = −0.170; P =
.045), T-regulatory cells (r = −0.395; P = .002), and B-
cells (r = −0.212; P = .012). These findings are similar
to our findings above. Also our results were consistent with
those presented above for the entire study group and for HIV
negative participants.
4. DISCUSSION
To identify possible correlates that may underlie the inter-
action of AF-ALB with HIV disease progression, we sought
to identify immune perturbations that are common to both
conditions. This study demonstrated, for the first time,
associations of aflatoxin with immune parameters in HIV-
infected people.
The changes observed in CD3+, CD4+, and CD8+ T-
cell phenotypes, CD19+ B-cells and CD3-CD56+ NK-cells
in HIV positive compared to HIV negative participants
(intergroup comparison) in this study are consistent with
previously well-characterized, HIV-associated changes in
these cells. HIV-associated immune perturbations were
largely similar in participants with high and low AF-ALB
levels. HIV infection induced a decrease in CD4+ T- cell
numbers and concomitantly activated the immune system.
HIV infection was associated with greater expression of
HLA-DR/CD38 and lower expression of CD28 on CD4+ and
CD8+ T-cells. We found that the surface expression of HLA-
DR/CD38 in both CD4+ and CD8+ T-cells was significantly
increased in HIV positive participants. The means of CD4+
and CD8+ cells expressing HLA-DR/CD38 progressively
increased with advancing clinical disease as determined by
CDC stage (data not shown). Also there was a strong
negative correlation between both CD4+ T-cell percentage
and CD4+ T-cell count with HLA-DR+CD38+ expressing
CD4+ T-cells (data is not shown). This activated immune
phenotype has been extensively validated in prior studies
and demonstrates T-cell activation to be a strong prognostic
indicator for progression to AIDS [31–33]. T-cell activation
is believed to be the major cause of CD4+ T-cell depletion
in HIV infection, through a progression of activation-
induced cell death (AICD) [34–37]. The increased immune
activation together with increased viral replication causes
severe depletion of CD4+ T-cells, eventually leading to the
development of AIDS. Therefore, our data suggest that HLA-
DR/CD38 could be used as a progression marker in HIV-
infected Ghanaians as in HIV-infected North Americans
[38].
In the present study, the principal costimulatory
molecule CD28 has been uniformly downmodulated in
CD4+ and CD8+ T-cells in HIV infected participants.
Engagement of the CD28 molecule on CD8+ T lymphocytes
in HIV positive individuals during activation has been
reported to increase CD8+ T-cell proliferation and diﬀer-
entiation and to prevent apoptosis [39–41]. T-cell receptor
stimulation in the absence of CD28 often leads to anergy
and to cell death via apoptosis in HIV-infected patients [42].
Many studies have suggested that HIV induces dysfunction
of CD4+ and CD8+ cells by CD28 downregulation [43, 44].
The loss of CD28 expression on CD4+ and CD8+ cells
in HIV infected participants may be associated with the
functional defect of the T-cells and progression to AIDS.
CD8+ T-cells are very important lymphocyte subsets
in the immune response against HIV infection. Naive
CD8+ T-cells can diﬀerentiate into eﬀector-type CD8+ T-
cells after they have recognized MHC-matched antigens
and then express cytolytic molecules, such as perforin
and granzymes which are stored in intracellular granules.
Therefore, perforin is expressed in antigen-primed CD8+
T-cells with a cytolytic activity potential that contribute to
the inhibition of pathogen spread through immediate lysis
of infected cells [45]. In our study, the percentage of naive
CD8+ T-cells in HIV infected participants was lower than
in HIV negative controls, and the percentage of perforin
expressing CD8+ T-cells was significantly increased in the
HIV-infected participants than in HIV negative controls.
Our observation is consistent with other reports [33, 34].
Overexpression of perforin in HIV-infected participants may
be the consequence of CD8+ T-cell hyperactivation and
expansion as a part of feedback regulation of anti-HIV
cytotoxic T-lymphocyte (CTL) activity [46, 47]. However,
among both the HIV infected and HIV negative control
groups, those with high AF-ALB showed a lower percentage
of perforin expressing CD8+ T-cells compared to those
with low AF-ALB levels. This may indicate that CD8+ T-
cells synthesizing perforin to enhance the CTL response
are impaired in individuals with high AF-ALB [22]. Thus
cellular immune function against infectious diseases, such
HIV infection will be aﬀected.
T-regulatory cells (Tregs) represent 5–10% of peripheral
CD4+ T-cells in healthy individuals and are characterized
by constitutive expression of CD25+ and CD45RO+. Tregs
(CD4+CD25+CD45RO+) have been implicated in con-
trolling responses to chronic pathogens [48–50] and are
known to profoundly inhibit both CD4+ and CD8+ T-cell
activation, proliferation, and eﬀector function, although the
mechanism of this inhibition remains unclear. Thus Tregs
may play a critical role in limiting immunopathology that
results from persistent high level immune stimulation from
chronic viral infections [51]. We evaluated this population
of cells in HIV positive and HIV negative participants
for both high and low AF-ALB groups. We found that
CD4+CD25+CD45RA+ Tregs showed a tendency to decrease
in HIV infected participants with both high and low AF-ALB
level compared to HIV negative controls. In addition, we
found that the HIV positive group with high AF-ALB had the
lowest percentage of Tregs of all the groups suggesting that
there is a loss of Tregs in HIV infected participants with high
AF-ALB. This loss may facilitate the immune hyperactivation
associated with HIV and lead to more severe disease in those
with high aflatoxin levels.
The activation molecule CD69 is a costimulatory
molecule for lymphocyte proliferation. It is expressed early
on the membranes of T- and B-lymphocytes through the
stimulated antigen receptor/CD3 complex or cross-linking
of surface immunoglobulins, respectively. T-lymphocyte
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Table 2: Summary of the immune indices in which significant diﬀerences (P value) were identified by intra- and intergroup comparisons
among high and low aflatoxin B1 albumin adduct (AF-ALB) and HIV positive and HIV negative participants.
Cell subset (percentage)
Intergroup comparison Intragroup comparison
High AF-ALB Low AF-ALB HIV positive HIV negative
HIV positive versus
negative
HIV positive versus
negative
High versus Low
AF-ALB
High versus Low
AF-ALB
Lymphocytes (count) ↓ 0.003 ↓ 0.045
CD4+ cells ↓ 0.000 ↓ 0.000
CD4+ cells (count) ↓ 0.000 ↓ 0.000
CD4+CD28+ ↓ 0.000 ↓ 0.000
CD45RA+CD62L+CD4+ ↓ 0.029
CD45RO+CD45RA-CD4+
CD4+HLA-DR+CD38+ ↑ 0.000 ↑ 0.000
CD4+CD25+ ↓ 0.001 ↓ 0.016
CD4+CD25+CD45RO+ ↓ 0.000 ↓ 0.061 ↓ 0.009
CD4+CD25-CD45RO- ↑ 0.000 ↑ 0.000
CD4+CD25-CD45RO+ ↑ 0.000 ↑ 0.000
CD8 ↑ 0.000 ↑ 0.000
CD8+CD28+ ↓ 0.000 ↓ 0.000 ↑ 0.022
CD45RA+CD62L+CD8+ ↓ 0.017 ↓ 0.003
CD45RO+CD45RA-CD8+ ↑ 0.006 ↑ 0.002
CD8+HLA-DR+CD38+ ↑ 0.000 ↑ 0.000
CD8+CD27-CD45RA+ ↑ 0.038
CD8+CD27+CD45RA+ ↓ 0.03
CD8+CD27-CD45RA-
CD8+Perforin+ ↑ 0.000 ↑ 0.000 ↓ 0.012 ↓ 0.008
CD8+Granzyme A+ ↑ 0.000 ↑ 0.003
CD8+Granzyme A+Perforin+ ↑ 0.000 ↑ 0.002 ↓ 0.010
CD3-CD19+ ↓ 0.03
CD19+CD69+ ↓ 0.000 ↓ 0.027
CD3+
CD3+CD69+ ↓ 0.024
CD3-CD56+
CD3-CD16+CD56+ ↑ 0.052
CD3+CD56+Perforin
activation via CD69 will progress to proliferation, thus
amplifying immune responses [52]. In our present study,
the levels of CD69 expression on CD3+ subsets did not
diﬀer between the HIV positive and HIV negative control
groups. This supports the observation by Krowka et al. and
Bo¨hler et al. [53, 54] that unstimulated T-cells from HIV-
infected and negative control individuals exhibited similar
levels of CD69 expression [53, 54]. The reduced proportions
of T-lymphocytes coexpressing CD69 were seen only upon
mitogen stimulation in HIV-infected adults [53]. Among
HIV negative controls, the significantly decreased percentage
of CD69 on CD3+ T-cells was found in the high AF-ALB
group compared to the low AF-ALB group as reported
before [22]. This could partially contribute to the inability
of these cells to mount appropriate immune responses.
However, this tendency was not seen when we compared
the high AF-ALB group to the low AF-ALB group among
HIV positive participants. This finding probably reflects the
coexistence of immune activation as shown by increased
HLA-DR and CD38 expressing CD4+ and CD8+ T-cells, and
immune deficiency as shown by reduced numbers of CD4+
lymphocytes, and impaired T- lymphocyte proliferation in
HIV-infected individuals [55]. It has been reported that
there is the tendency for CD69 expression on unstimulated
peripheral blood T-cells to increase with plasma HIV viral
load [56]. Therefore, the variability in plasma HIV viral load
level may also contribute to our observation.
In keeping with findings of a previous study [22], we
found that high AF-ALB was associated with the reduced
percentages of unstimulated CD19+ B-cells coexpressing
CD69 in both HIV infected and control groups, but only
the diﬀerence for the HIV negative groups reached statis-
tical significance. HIV infection was also associated with
decreased CD19+CD69+ B-cells in both groups but only
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the diﬀerence for the low AF-ALB group reached statistical
significance. No previous data exist concerning the CD69
expressing B-cell in HIV-infected adults. However, there
are some reports that have shown that HIV-induced B-cell
hyperactivity is associated with reduction of CD21 [57], and
CD27 [58, 59] expression in HIV infected patients. Ginaldi
et al. [60] reported that B-cells from HIV infected patients
show a significantly lower number of HLA-DR molecule per
cell compared to normal controls. Our study shows that
the ability of B-cell to express CD69 has been impaired in
both high AF-ALB exposure and HIV infection. This could
suggest that AF-ALB may accentuate the changes in HIV-
related immune parameters.
High aflatoxin appeared to accentuate some HIV-
associated changes in T-cell phenotypes and B-cells in HIV-
infected participants. Because of the cross-sectional design
of this study, however, we cannot exclude the possibility
that these intragroup diﬀerences may simply reflect an
imbalance in the severity of HIV disease, with more advanced
disease (not evident by our CDC classification) in the
high AF-ALB group. However, despite these limitations, we
believe that this study has a potentially significant impact
on understanding the eﬀects of aflatoxin in HIV disease
progression.
A better understanding of the interaction of high
aflatoxin with HIV disease might provide insight into key
mechanisms that underlie the immunopathogenesis of both
processes. Potential immune correlates of this interaction
may include reduced Tregs, impaired CD8+ T-cell func-
tion, plus impaired B-cell CD69-expressing ability. In HIV-
infected patients with higher AF-ALB, loss of Tregs, and
persistent immune activation might lead to exhaustion of
the naive CD8+ T-cell pool, uniform downmodulated of
the principal costimulatory molecule CD28 on CD8+ and
CD4+ cells, impaired function of CD8+ T-cells synthesizing
perforin (which results in failure of cytolysis by CD8+ T-
cells), plus impaired ability of B-cell to express CD69. This
will result in increased viral replication and increase in the
occurrence of viral escape mutants. Because of viral escape,
viral load will increase resulting in further loss of functional
HIV specific CD4+ T-cell and a progressive deterioration of
the immune system.
Given these observations, high aflatoxin may promote
more rapid HIV disease progression in HIV-infected Ghana-
ians. Our findings should be considered exploratory, given
the cross-sectional design of this study and because there may
be other variables not considered that may aﬀect immune cell
distribution and function. Further clarification of these and
other possible immune correlates of the interaction of high
aflatoxin with HIV disease progression might be aﬀorded by
additional investigation.
5. CONCLUSION
High AF-ALB appeared to accentuate some HIV-associated
changes in T-cell phenotypes and B-cells in HIV positive
participants. These results may indicate that CD8+ T-cells
synthesizing perforin to enhance the CTL response are
impaired in individuals with high AF- ALB. The loss of Tregs
in HIV positive participants with high AF-ALB may facilitate
HIV associated immune hyperactivation and lead to more
severe disease.
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